

Aspergillosis: A comprehensive review of pathogenesis, drug resistance, and emerging therapeutics

Amanpreet Singh ^{a,*} , Jeewanjot Singh ^b , Sandeep Kumar ^a 

^a Department of Pharmaceutics, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Ropar, 140111, Punjab, India

^b Department of Pharmacology, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Ropar, 140111, Punjab, India

Abstract

Aspergillosis stands as a primary opportunistic fungal infection which mainly results from *Aspergillus fumigatus* events that have gained more importance because of its multiple infection patterns and developing antifungal resistance. Healthcare providers identify two main ends of the aspergillosis spectrum which include allergic responses and invasive systemic infections that affect mainly immunocompromised subjects. This review presents a detailed summary for understanding the epidemiology of aspergillosis along with its risk factors as well as pathogenesis and host immune response and diagnostic difficulties. The analysis puts significant weight on increasing azole and echinocandin resistance that has become worse because of agricultural and environmental azole exposure and the development of multidrug-resistant strains. The mechanisms of action and restrictions together with resistance profiles differentiate different antifungal treatments like azoles and echinocandins in addition to polyenes from each other. The potential therapeutic benefits of using combination therapy with drug delivery targeting systems and developing new antifungal agents including rezafungin and ibrexafungerp are assessed. The review emphasizes relevant interactions between drugs when used together with food elements which affect antifungal safety and effectiveness specifically in patients with complex healthcare needs. The review analyzes newly developed diagnostic methods including PCR-based tests and biomarkers for their capability of improving fast and precise detection. The review presents immunomodulatory therapies as well as host-directed strategies which represent a set of emerging approaches. The clinical presentation of aspergillosis varies widely which case studies help doctors to understand better. Comprehensive management of aspergillosis necessitates cooperative medical care and precise medicinal interventions alongside continuous diagnostics improvements to achieve solutions for the worldwide health issue.

Keywords: Antifungal resistance, Aspergillosis, *Aspergillus* species, Diagnostics, Global health

1. Introduction: the burden of aspergillosis

The fungal disease aspergillosis continues to develop into a major worldwide healthcare issue because it includes several diseases which *Aspergillus* species generate [1–3]. *Aspergillus* spores that exist widely throughout the environment continue to cause this opportunistic infection because of increasing numbers of immunocompromised people [1]. A complete evaluation of

aspergillosis analyzes its widespread patterns in combination with its disease mechanisms and its effects on human immunity and its various symptoms and its advancing resistance to medications. A complete knowledge of these intricate aspects stands vital for improving fatal fungal infection diagnosis and creating effective treatment approaches [4,5]. Research indicates that although *Aspergillus fumigatus* serves as the most prevalent cause of infection doctors also identify *Aspergillus*

Received 19 April 2025; accepted 5 May 2025.
Available online 13 June 2025

* Corresponding author at: Department of pharmaceutics, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Ropar, 140111, Punjab, India.
E-mail addresses: sainiamanpreet9878@gmail.com (A. Singh), sandhujeewan7@gmail.com (J. Singh), drsandeeprajputra@gmail.com (S. Kumar).

<https://doi.org/10.38212/2224-6614.3547>

2224-6614/© 2025 Taiwan Food and Drug Administration. This is an open access article under the CC-BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

flavus, *Aspergillus niger* and *Aspergillus terreus* as important disease-causing agents which show different virulence patterns and clinical features [6–8]. Medical diagnosis of *Aspergillus fumigatus* requires a refined approach because the infection can manifest from minimal allergic reactions to fatal invasive medical conditions [9]. Fig. 1.

2. Epidemiology: global distribution and risk factors

2.1. Global prevalence and incidence

The difficulty to obtain exact global numbers for aspergillosis prevalence and incidence continues to persist because of multiple obstacles. The diagnosis of aspergillosis faces difficulties in mildly affected cases because of improper diagnosis methods and inconsistent reporting approaches between geographical areas and healthcare facilities [10–12]. The analysis of particular demographic groups or particular regions helps create useful knowledge yet proves unsuitable for developing official global statistical information. A Brazilian prospective research found that candidemia occurred at rates 3–15 times higher than North American and European studies recorded [10]. Opportunistic fungal infections show substantial differences regarding their distribution within different geographic areas. Invasive aspergillosis presents a high incidence among immunocompromised patients according to studies [4,5,13] as this population continues to grow because of medical progress in transplantation and cancer therapy [5]. The COVID-19 pandemic has introduced additional complications to health care since COVID-19-associated pulmonary

aspergillosis (CAPA) has become a significant concern for medical professionals [12,14]. Clinicians report different CAPA occurrence rates in their case studies which can vary from below 5% to above 30% throughout the literature [12]. Therefore, standardized diagnostic and reporting standards need development. Diagnostic reports show that *A. fumigatus* exists across the world but other *Aspergillus* species exist in specific regions based on climate patterns and environmental elements.

2.2. Risk factors for aspergillosis

Many elements enhance the risk level for developing aspergillosis among individuals. The occurrence of immunocompromised states represents major risk factors that cause people to develop IA according to Refs. [4,5,15,16]. The combination of neutropenia (low neutrophil count) with organ transplantation and HIV infection and their necessary immunosuppressive drugs creates a perfect environment for susceptible individuals to develop aspergillosis [5]. Cystic fibrosis, tuberculosis and chronic obstructive pulmonary disease (COPD) together with existing lung conditions significantly boost the risk of aspergillosis [17–19]. *Aspergillus* finds a hospitable environment to colonize and infect the respiratory tract because these pre-existing conditions cause either lung damage or destroy immune system function [17]. The opportunity to breathe high levels of *Aspergillus* spores constitutes a primary hazard condition for infection development. Professional occupational contact with window (errors) areas of agricultural zones or construction sites that harbor high concentrations of *Aspergillus* spores leads to significant infection threats [7,20]. The use of corticosteroids along with other immunosuppressive drugs stands as a primary risk factor because it weakens the immune system thus making individuals more prone to aspergillosis infections [12–14]. The extended administration of medication involving these drugs for medical management purposes creates patients more susceptible to opportunistic fungal infections.




Fig. 1. Morphology of *Aspergillus*.

3. Pathophysiology: from spore to disease

3.1. Inhalation and germination

Inhalation of *Aspergillus* conidia leads to the start of the *Aspergillus* infection [3,15,17]. Inhaled *Aspergillus* spores measure just microns large but can smoothly travel to the small lung air sacs named alveoli [15]. The transportation of such airborne conidia into alveoli depends on both external environmental

spore concentrations and internal factors that affect the respiratory health of patients. After reaching the alveoli the conidia start to germinate thus starting the infection process. The process of germination depends on genetic activation as well as enzyme production that dismantles the conidial cell wall [21]. Germination of conidial cells primarily depends on temperature levels and humid air along with necessary nutrients in the surrounding environment [21]. The immune response of the host determines germination significantly because both immune cells and antimicrobial peptide production controls this process [22]. Germination occurs throughout the immune response in immunocompromised individuals because their insufficient immune response fails to impede conidial development thus establishing infection.

3.2. Hyphal invasion and tissue damage

The growth of hyphae follows successful seed germination because *Aspergillus* produces these microscopic filamentous structures. The fungal cells penetrate around lung tissue while penetrating through alveolar epithelium and advancing toward the interstitial space [21,23]. The invasive abilities of *Aspergillus* hyphae depend on the manufacture of different enzymes and toxins to enhance their growth [24]. The precise tissue breakdown during hyphal penetration depends on three classes of enzymes which include proteases together with lipases and other hydrolytic enzymes [24]. The

immunosuppressive toxin gliotoxin works as an inhibitor that makes it harder for the host to manage the infection [25]. The combination between *Aspergillus* species virulence and the capability of the immune defense to contain the infection determines the extent of tissue damage [21]. Lack of effective immune response by immunocompromised persons leads to uncontrolled hyphal invasion causing both severe damage to tissues and progression of the disease.

3.3. Dissemination and systemic infection

In critical cases involving immunosuppressed individuals, the fungus proliferates by infiltrating blood vessels, facilitating its distribution throughout the body via the circulatory system. [2,5,26]. The fungus moves between lungs and other body parts after lung infection because of disseminated aspergillosis [2]. Broadcast of the fungus occurs most frequently among brain tissue along with kidney tissue, heart tissue and skin tissue [27]. The life-threatening event called disseminated aspergillosis frequently results in death through multi-organ failure since it persists at high mortality rates [5]. The capability of *Aspergillus* to spread depends on the fungal strain's virulence properties together with the intensity of immunosuppression in addition to treatment success with antifungal drugs [5]. Timely diagnosis coupled with suitable medical treatments remain essential to block *Aspergillus* spread and achieve better patient results. Fig. 2.




Fig. 2. This figure describes the pathogenesis of *Aspergillus* infection through the respiratory system after inhalation of fungal spores in the lungs. Spores get into the airways, causing irritation and damage to cilia, essential for clearing mucus and debris from the respiratory tract. The infection continues and reaches the alveoli where inflammation occurs due to immune response. Lethal cases of aspergillosis can experience necrotizing pneumonia with invasion of blood vessels (angioinvasion), allowing fungal elements to enter the blood and disseminate, resulting in systemic infection. This figure illustrates the major pathological stages of *Aspergillus*-associated lung diseases that may be severe in immunocompromised individuals.

4. Host immune interactions: a complex defense system

4.1. Innate immunity: first line of defense

According to research publications [24,28] the innate immune system takes the essential protective role for preventing *Aspergillus* infections. This rapid and non-specific pathogen identification system depends on different cells and molecular components which defend tissues from invading pathogens [24]. The alveolar resident phagocytes known as pulmonary macrophages become among the earliest cells to encounter inhaled *Aspergillus* conidia according to Refs. [21,22]. The macrophages detect *Aspergillus* conidia through pattern recognition receptors (PRRs) which include Toll-like receptors (TLRs) and dectin-1 that recognize the fungal pathogen-associated molecular patterns (PAMPs) on the surface [21]. The receptor activation prompts sequential biological signaling which then generates inflammatory cytokines while activating other immune cells [24]. A tissue infection results in neutrophil cell recruitment to the area for critical hyphal destruction during the infection process [22]. Infections can be effectively controlled through the initial stages and establishment can be prevented by a fully functional immune response [28].

4.2. Adaptive immunity: targeted response

The adaptive immune system becomes active when the innate immune system fails to eliminate the infection by providing a more targeted along with specific response [24]. The immune process activates T lymphocytes together with antibody production [24]. Th cells function as the main regulators of adaptive immune response actions [24]. *Aspergillus* protective immunity results mainly from Th1 cells producing interferon-gamma (IFN- γ) [24]. When stimulated by IFN- γ macrophages become more potent killers of *Aspergillus* [24]. Some instances show a domination of the Th2 response which results in interleukin-4 (IL-4) and IL-10 secretion [25,29]. The allergic manifestations of aspergillosis such as aggressive bronchopulmonary aspergillosis (ABPA) typically appear when this immune response occurs [25,29]. Researchers presently examine the contribution of Th17 cells to aspergillosis pathogenesis [24]. Through antibody production B cells enable the immune response to bind with *Aspergillus* antigens which improves fungal elimination [24].

4.3. Immune evasion strategies of *Aspergillus*

Aspergillus species have developed various tactics to escape the host defense mechanisms thereby improving their capability to become established within the body [24]. The microorganism produces the immunosuppressive toxin gliotoxin as one important defense mechanism [25]. The secondary metabolite gliotoxin produced by *A. fumigatus* works as an immune cell blockage agent which weakens the immune function of the host [25]. *Aspergillus* cells organize into biofilms by assembling themselves with an extracellular matrix material [21]. *Aspergillus* uses biofilms to create shielded structures which block phagocytic protection along with antifungal medications [21]. The fungus adapts its cell wall elements to escape detection by PRRs which results in diminished host ability to find and destroy the fungal cells [21]. The methods *Aspergillus* uses to evade immune responses help it cause continuous infections which spread throughout the body especially among people who have weakened immune systems.

5. Clinical manifestations: a diverse spectrum of disease

The many forms of aspergillosis illness emerge from a combination of infecting *Aspergillus* species alongside site of infection and host immune condition [2,9]. The disease manifestations display diverse forms because of different pathogen-host immune system interactions.

5.1. Invasive aspergillosis (IA)

The most dangerous manifestation of aspergillosis occurs when *Aspergillus* hyphae invade tissues directly and presents as invasive aspergillosis (IA) [1,5,12]. This dangerous condition becomes very dangerous for people whose immune systems cannot fight properly [5]. Pulmonary invasive Aspergillosis stands as the primary presentation since it causes *Aspergillus* infections to target the lungs first [5]. Patients experiencing the symptoms include fever accompanied by cough along with dyspnea (shortness of breath) and chest pain [5]. The characteristic findings of nodules with cavities and infiltrates appear regularly on chest X-rays and CT scans during imaging studies [5]. Severe instances of IA lead to organ spreading those results in multi-organ failure accompanied by mortality [5]. The successful treatment results from early diagnosis and immediate administration of antifungal medications [5].

5.2. Chronic pulmonary aspergillosis (CPA)

CPA stands as a milder form of aspergillosis which affects immunocompetent patients who possess tuberculosis and COPD and sarcoidosis similarly [9]. The lung tissue condition known as CPA allows *Aspergillus* to grow within current lung lesions or cavities. Doctors often observe patients with chronic cough together with hemoptysis (coughing up blood) and general bodily fatigue symptoms [30]. The lung tissue shows cavities and nodules and fibrosis through imaging tests [30]. The standard treatment for CPA requires long-term antifungal medications and surgical removal becomes an option in particular cases of localized disease [30].

5.3. Allergic bronchopulmonary aspergillosis (ABPA)

The hypersensitivity reaction known as allergic bronchopulmonary aspergillosis (ABPA) mainly affects people with asthma or cystic fibrosis [18,31,32]. The main features of allergic bronchopulmonary aspergillosis include recurrent asthma episodes along with pulmonary infiltrates and elevated eosinophil counts and IgE levels [18,31]. Asthmatic patients with *Aspergillus* exposure develop wheezing and cough together with shortness of breath according to Refs. [18,31]. Doctors treat this condition using antifungal agents and corticosteroids both to control existing inflammation and fungal growth [18,31]. Fig. 3.

5.4. Other manifestations

The body parts affected by *Aspergillus* can encompass the sinuses (resulting in sinusitis) along with the cornea (leading to keratitis) and also impacts the heart by causing endocarditis [2,33–35]. The extent of disease progression shifts between limited and widespread form based on the immune capabilities of the host along with the pathogenic potential of the infected *Aspergillus* species. The signs and symptoms of extrapulmonary *Aspergillus* infections develop according to where the infection exists and how extensive it becomes. The medical diagnosis depends on imaging examinations combined with affected tissue cultures followed by serological examinations [2].

6. Drug resistance mechanisms: a growing threat

Among those, *A. fumigatus* has been accused to be in the global rise of antifungal drug resistance in *Aspergillus* species, making it a major threat to the effective treatment of aspergillosis [1,36,37]. The emergence of resistance pathways causes a reduced antifungal treatment efficacy since it reduces the efficacy of existing treatments and contributes poor treatment results along with higher death rates [1].

6.1. Azole resistance: a major concern

The treatment of aspergillosis mainly depends on azoles that function against the fungal enzyme




Fig. 3. This fig. shows the potential outcome of *Aspergillus* according to immune status and lung status and event progression. In those with immunocompromising conditions, IPA presents as a severe acute illness. Even patients with chronic lung disease may develop CPA, which is a non-invasive but destructive form of the mycotic infection. An allergic response in patients with asthma or cystic fibrosis leads to allergic bronchopulmonary aspergillosis (ABPA). This figure also emphasizes transitional and overlapping stages between these states.

cytochrome P450 lanosterol 14 α -demethylase (CYP51) which is essential for ergosterol biosynthesis [1,5,8]. The *cyp51* a gene which codes for CYP51 protein displays mutations as the primary reason for azole resistance [1,36–38]. The enzyme loses its ability to bind azole pharmaceuticals because mutations affect enzyme structural configuration [1]. Two specific mutations TR34/L98H and TR46/Y121F/T289A confer extraordinary azole resistance while being highly prevalent in the fungal population [1,36]. Agricultural use of azole fungicides played a major role in selecting and spreading azole-resistant *A. fumigatus* strains based on available research [36,39]. Overexpression of efflux pumps that actively remove azoles from fungal cells plays a role in creating drug resistance [1] together with [40].

6.2. Echinocandin resistance: an emerging threat

Patients benefit from echinocandin anti-fungal medication through its specific action on β -1,3-D-glucan synthase to prevent cell wall formation in aspergillosis treatment [5]. The occurrence of echinocandin resistance tends to be lower than azole resistance yet it is currently becoming more widespread [41]. The main cause behind echinocandin resistance is mutations in the FKS gene which creates β -1,3-D-glucan synthase [41]. The structural modifications occurring from these mutations make the enzyme less compatible with echinocandin medications and result in drug resistance behavior [41].

6.3. Multidrug resistance: a complex problem

Multidrug resistance in which *Aspergillus* strains demonstrate opposition to several different antifungal drug categories presents a severe medical challenge [41,42]. Two sources of multidrug resistance in *Aspergillus* strains include the growth of a single strain containing various resistance mechanisms and microbes exhibiting intrinsic resistance to multiple treatment classes [41]. The treatment of multidrug-resistant *Aspergillus* strains remains very challenging because it results in high fatality rates [41]. The spreading rates of multidrug resistant strains call for rapid development of better antifungal treatments and prevention approaches.

7. Current antifungal therapies: mechanisms and limitations

Treatment of aspergillosis relies mainly on polyene medications which belong to the same group with azoles and echinocandins. The different classes

of antifungal drugs affect fungi through distinct biological mechanisms but present distinct obstacles related to treatment effectiveness and toxicity and drug-resistant development.

7.1. Polyenes (e.g., Amphotericin B)

The antifungal drug Amphotericin B (AmB) has served as an essential treatment method since its initial utilization in 1950s [43]. Binding to ergosterol forms the first step of its action because ergosterol serves as an essential building block of fungal cell membranes [44]. The membrane attacks from the drug result in the formation of pores which culminates in fungal cell demise [44]. The clinical application of AmB faces significant restrictions because of its severe toxic side effects. The occurrence of nephrotoxicity raises a major concern since physicians report it frequently in their practice [43,45]. The medical usage of this drug is restricted due to multiple adverse effects which include infusion-related reactions along with hypokalemia and hepatotoxicity [43].

The development of the liposomal formulation of AmB (AmB-LLs) serves to minimize toxic effects [45]. The liposomal formulations of AmB protect the antimycotic agent by enclosing it inside liposomes leading to reduced host cell contact which decreases the toxicity effects [45]. The safety improvement of AmB-LLs versus standard AmB treatment remains high but these drug formulations still present specific limitations. Fungal cell mortality remains insufficient as a major concern especially when treating severe IA cases [45]. The development of AmB resistance from *A. terreus* along with intrinsically developed resistance [46] requires healthcare providers to search for new therapeutic options [43]. Several regions in the world face difficulties to obtain AmB-LLs due to their expensive manufacturing cost structure.

7.2. Azoles (e.g., voriconazole, itraconazole)

Among the azoles family that physicians use to cure aspergillosis are the antifungal compounds voriconazole and itraconazole. Azole, an antifungal agent, inhibits the synthesis of fungal enzyme lanosterol 14 α -demethylase, which is essential for ergosterol generation [44]. Azoles cause fungal cellular death and damage fungus cell membranes when they block ergosterol production, thereby aggravating fungal cellular damage [44]. Because it shows both wide antifungal activity and right therapeutic effects, physicians first pick voriconazole for intravenous aspergillosis treatment.

Azoles' therapeutic advantages come with several limiting factors. As noted in Ref. [44], drug–drug interactions provide a significant clinical issue for patients being treated with the triazole medicine voriconazole. Although usually controllable with monitoring, the possibility for hepatotoxicity calls for thorough patient selection and conscientious clinical observation. The most serious challenge azoles provide to treatment is resistance emergence. Azole resistance, primarily resulting from modifications in the ERG11 gene responsible for encoding lanosterol 14 α -demethylase [47], triggers the gradual development of azole-resistant in distinct stages. Specific mutations (TR34/L98H or TR46/Y121F/T289A) found in environmental triazole fungicide-exposed areas call for urgent medical intervention, therefore *fumigatus* strains become more and more important [48]. Because of their reduced drug response, the drug-resistant strains exhibit lower sensitivity to single or multiple azole treatments.

7.3. Echinocandins (e.g., caspofungin, micafungin)

New agents in the echinocandin antifungal drug class including caspofungin and micafungin inhibit the fungal cell wall [44]. These compounds inhibit the operation of 1,3- β -D-glucan synthase, an essential enzyme needed to produce 1,3- β -D-glucan found in fungal cell walls [44]. Inhibition of fungal 1,3- β -D-glucan synthase enzyme activity weakens cell walls, therefore allowing osmotic stress and final fungal cell death to occur [44]. Patients tolerate echinocandins well since the medication profile of theirs is safe [44].

When echinocandins medicines are used, treatment of aspergillosis is severely limited. Echinocandins' anti-*Aspergillus* activity is less strong than that of azoles, according to data [49]. Studies show that medical care is increasingly threatened by resistance to echinocandins [47]. Echinocandin resistance arises mainly from FKS mutations and dysfunction that changes the target enzyme 1,3- β -D-glucan synthase [47]. Since these variations cause the drug binding affinity to drop and the echinocandin sensitivity to fall, among patients with acute myeloid leukemia, a research study comparing caspofungin to fluconazole as prophylaxis treatments showed lower incidence of invasive fungal disease among those given caspofungin therapy [50]. Further research is necessary to establish the complete clinical worth of echinocandins especially for aspergillosis therapy in specific patient populations.

7.4. Other antifungal agents

Echinocandins together with polyenes and azoles serve as primary antifungal agents but alternative antifungal classes show limited applications in treating aspergillosis [43]. The antifungal agent terbinafine belongs to the allyamine category which affects the enzymatic activity of squalene epoxidase which participates in ergosterol biosynthesis [43]. Pyrimidine antimetabolites, like flucytosine, interfere with fungal DNA and RNA synthesis [43]. Griseofulvin functions as a mitotic inhibitor that disrupts fungal cell division through microtubule dysfunction [43]. Nevertheless, these antifungal medications commonly encounter problems with minimal antimicrobial range and dangerous side effects and developing resistance [43]. These drugs come into use mainly during specific circumstances where they work alongside additional antifungal treatment medications. New antifungal medications must be developed because the few available drug classes and growing treatment resistance require effective antifungal compounds which offer better safety alongside stronger therapeutic results.

8. Novel antifungal strategies: targeting drug resistance and enhancing efficacy

Scientists use novel antifungal strategies to develop better treatment approaches because existing therapies fail to restrict fungal infections adequately. The strategies involve either bypassing currently observed drug resistance characteristics or maximizing the effects of current antifungal therapeutic agents.

8.1. Novel antifungal drugs

Scientists identify positive signs in the development of new antifungal medications [51]. Rezafungin, a novel echinocandin, stands out due to its unique pharmacokinetic/pharmacodynamic (PK/PD) profile [52,53]. The extended period in which the drug remains active enables doctors to prescribe drugs only once per week which enhances adherence through simplified treatment strategies [52,53]. Research has shown that rezafungin successfully stops and cures invasive candidiasis and aspergillosis infections in mouse experimental models according to studies published in Refs. [52,53]. Scientists classify the triterpenoid glucan synthase inhibitor ibrexafungerp as a potential leading antifungal candidate [54,55]. Drug experts view ibrexafungerp favorably because it offers oral treatment

availability and kills a wide range of fungal microorganisms along with resistant azole strains [54,55]. Olorofim stands as a novel antifungal agent which focuses on fungal mitochondrial ATP synthase as its target [51] to provide potential options for fighting resistance against current antifungal drugs. The present preclinical research supports these innovative antifungal agents but human clinical trials must take place to prove their safety and efficacy for medical use.

8.2. Targeted drug delivery

The objective of targeted drug delivery systems consists of enhancing the efficacy and safety of antifungal therapy through precise drug delivery to fungal infection areas and reduced exposure of well cells [45,56]. Liposomes containing antifungal drugs receive ligand-based coats that show selective binding properties for fungal cell receptors [45,56]. Through targeted delivery the medication accumulates better in infected areas leading to increased effectiveness along with reduced total dosage demands that result in decreased systemic toxicities [45,56]. The antifungal efficacy of liposomal AmB increased significantly when researchers targeted DEC-AmB-LLs toward Dectin-1 receptors in *A. fumigatus* tests compared to untargeted liposomes according to studies [45]. Liposomal AmB that targets Dectin-2 receptors proved effective against infections caused by *Candida albicans*, *Cryptococcus neoformans* and *A. fumigatus* according to research [56]. Targeted drug delivery has brought forward major improvements in antifungal therapy through improved clinical results and diminished side effect occurrence.

8.3. Combination therapy

Researchers show Growing Interest in Combination therapy because it demonstrates potential benefits for both treatment response strength and drug resistance failures [57]. When healthcare professionals apply multiple antifungal drugs they can create beneficial treatment effects while expanding the treatment range and minimizing the possibility of the fungus becoming drug-resistant. The use of combined medication treatments helps successfully fight infections from fungi that have become resistant to multiple drugs because single-drug therapy proves ineffective. The medical basis for combination therapy begins with the belief that simultaneous action on various fungal cellular pathways enables greater fungal destruction and leads to better treatment results.

A combination of antifungals expands therapeutic effects and decreases negative side effects relative to single-drug usage [58]. The activity scope of antifungal drugs remains restricted because these medications work effectively against specific types of fungi. When healthcare providers combine antifungals that target different pathogens it enlarges the number of susceptible fungal infections improving the chance of therapeutic success. Combination antifungal therapy permits medical staff to administer decreased dosages of individual components compared to monotherapy thus minimizing toxic risks.

The combined effects of antifungal medications demonstrate better treatment potential for challenging fungal infections that do not respond well to standard therapies. A synergistic effect exists when multiple antifungal drugs produce a stronger combined impact than the effects generated by their independent use. The combined effect results in more effective fungal destruction and enhanced medical results when dealing with fungal infections which do not respond well to single-drug treatment. Antifungal drugs work better together to override resistance mechanisms which result in increased susceptibility of fungi to the agents.

8.4. Common antifungal combinations used in aspergillus treatment

8.4.1. Azoles and echinocandins

Medical professionals use the combination of azoles with echinocandins as a standard therapeutic practice especially for difficult-to-treat aspergillosis cases [59,60]. Salvage therapy commences after either initial antifungal treatment fails to remove *Aspergillus* or when substantial adverse effects occur from initial treatment drugs. Medical professionals administer antifungal drugs from different classes to improve treatment effectiveness in such cases. Professional medical circles favor using echinocandin drugs alongside azoles as salvage antifungal therapy because these agents act differently and generate enhanced treatment benefits together.

This combination aims to leverage the distinct mechanisms of action of each drug class [61]. The cell membrane essential component ergosterol faces inhibition by azoles including voriconazole, itraconazole, posaconazole and isavuconazole in their mechanism of action. The fungal cell wall component beta-1,3-glucan undergoes inhibition by echinocandin drugs such as caspofungin, micafungin and anidulafungin. The dual attack on essential fungal structures through this therapy disrupts

cellular growth which results in death of fungal cells.

Several laboratory tests with animal subjects indicate that partnerships to fight *Aspergillus* spp. could result in combined or duplicated treatment outcomes. [62,63]. In test tube studies scientists discovered that echinocandins combined with azoles produce synergistic antifungal effects against *Aspergillus* species which equal the greater of the two effects or their merged outcomes. In animal models of infections medical practitioners have observed that combining azole medications with echinocandin drugs leads to superior clinical results compared to treating patients solely with these individual classes. The combined treatment demonstrates potential for clinical setting when healthcare providers recommend it especially for refractory IA patients and those who are at high risk for treatment failure.

8.4.2. Caspofungin and amphotericin B

Clinical evidence reveals that Caspofungin works synergistically with amphotericin B when treating neurotropic dematiaceous fungi [64]. Neurotropic dematiaceous fungi constitute a dark-pigmented mold cluster which induces serious central nervous system infections that result in cerebral phaeohyphomycosis. Antifungal treatments fail to penetrate the brain effectively and multiple fungi demonstrate natural resistance to standard antifungal medications which makes these infections challenging to treat. *In vitro* tests indicate that combined exposure of caspofungin and amphotericin B against these fungi shows improved antifungal performance which suggests potential value as cerebral phaeohyphomycosis treatment.

Experimental research verifies that this combination demonstrates potential for cerebral phaeohyphomycosis treatment [64]. The central area of the brain becomes susceptible to death through cerebral phaeohyphomycosis which arises from dematiaceous fungi infections. Patients usually require surgery to remove infected tissue along with antifungal medical treatments. Medical professionals successfully treat specific cases of cerebral phaeohyphomycosis by combining caspofungin with amphotericin B when the infection resists alternative antifungal agents.

The laboratory research investigates how the combined use of these agents affects *Candida* species [65]. The main targets of the caspofungin and amphotericin B combination against *Aspergillus* fungi along with dematiaceous fungi have yielded research toward evaluating their reaction against *Candida* species in tests. Several scientific studies demonstrated that this dual antifungal therapy

exhibits cooperative action against selected *Candida* species which indicates its potential to improve candidiasis treatment where azole-resistant *Candida* exists.

8.4.3. Caspofungin and flucytosine

Experimental results demonstrated that the effects of combining caspofungin with flucytosine against *Fonsecaea monophora* one isolate became synergistic when combined with amphotericin B or posaconazole treatment [64]. The chronic skin infection and rare cerebral infection known as chromoblastomycosis along with cerebral phaeohyphomycosis develop from *Fonsecaea monophora* infections of the dematiaceous fungus type. *In vitro* tests demonstrate that the combination of caspofungin as well as flucytosine together with amphotericin B or posaconazole creates synergistic antifungal effects against *F. monophora* which suggests these drugs could prove useful for treating infections from this fungus.

The combination of amphotericin B together with caspofungin and flucytosine showed synergistic effects against *Cladosporium cladosporioides* [64]. Humans commonly encounter *C. cladosporioides* which belongs to the group of dematiaceous fungi found throughout the environment but it rarely leads to infections mostly affecting immunocompromised people. Laboratory tests show the triple treatment of amphotericin B together with caspofungin and flucytosine exhibits synergistic effects toward inhibiting *C. cladosporioides* fungus making this combination potentially valuable for fungal infection treatments.

The potential existence of this drug combination suggests attractiveness for cerebral phaeohyphomycosis treatment [64]. The observed synergistic effect between caspofungin and flucytosine during laboratory tests indicates that using this drug combination with amphotericin B or posaconazole shows promise as therapy for cerebral phaeohyphomycosis. The available evidence for using this treatment blend as a therapeutic plan for this specific case remains scarce because additional assessment of both its safety and performance needs to be undertaken.

8.4.4. Other clinically relevant antifungal combinations

8.4.4.1. *Voriconazole and caspofungin*. Solid organ transplant recipients demonstrate response to primary invasive aspergillosis treatment using the combination of voriconazole and caspofungin according to research by Ref. [66]. IA development is a significant risk for solid organ transplant recipients

because their weakened immune system results from immunosuppressive treatment. Clinicians use voriconazole as one of the first treatment options for IA yet caspofungin functions as an echinocandin by blocking fungal cell wall synthesis. Researchers have investigated voriconazole and caspofungin as first-line therapy for invasive aspergillosis in this patient demographic to achieve better results.

Some experts believe this treatment combination could provide optimal results when treating specific cases of aspergillosis which are caused by *A. fumigatus* [66]. Research indicates that using captcha and voriconazole as a treatment for *A. fumigatus* infections might yield maximum effectiveness in fighting common cases of invasive aspergillosis. The synergic drug effect against *A. fumigatus* plus the different approaches to fighting the pathogen result in this treatment's effectiveness.

This drug combination has undergone laboratory-based studies which examined its effects against *Aspergillus* species [62]. Laboratory experiments reveal that the joint therapeutic use of voriconazole and caspofungin produces combined antifungal effects that either support or supplement each other against different *Aspergillus* fungi. Medical usage of this drug combination receives support from these research findings.

8.4.4.2. Isavuconazole and echinocandins. Research teams have studied *in vitro* conditions of isavuconazole with echinocandins to test their combined effect against *Aspergillus* strains [67]. Isavuconazole functions as a newer triazole antifungal medicine which exhibits broad destructive properties against different fungal organisms including *Aspergillus* species. Laboratory studies have analyzed the drug interaction of isavuconazole with echinocandins like caspofungin, micafungin and anidulafungin toward different *Aspergillus* strains to evaluate potential synergy or antagonism effects or addition effects.

The checkerboard method detected no specific effect between isavuconazole and all tested strains according to research [67]. The checkerboard method stands as one of the commonly used *in vitro* techniques for evaluating the interactions between two or more antifungal agents. Antifungal agents of different concentrations are arranged in a checkerboard pattern during this method while researchers measure fungal growth at each tested concentration. Studies with checkerboard assays establish indifferent interactions between isavuconazole and echinocandins where their overall effect remains equivalent to the separate antifungal effects.

The interaction between isavuconazole-micafungin and isavuconazole-anidulafungin showed

indifferent effects on agar tests while the combination of isavuconazole-caspofungin demonstrated some synergistic and antagonistic results [67]. The mode of assessment for assessing isavuconazole-echinocandin drug interactions utilizes Agar-based diffusion procedures. Discs containing antifungal agents are placed on agar plates inoculated with fungus to determine the areas of inhibition surrounding each disk through this method. The interaction tests between isavuconazole and micafungin or anidulafungin produce indifferent results yet the isavuconazole-caspofungin interaction effects vary based on the particular *Aspergillus* strain between synergistic and antagonistic outcomes.

8.4.4.3. Posaconazole and lopinavir. Lopinavir (LPV) serves to increase the susceptibility of *A. fumigatus* strains to azoles and simultaneously decrease the amount of required azole needed for treating susceptible isolates [68]. The antiviral medication Lopinavir serves as standard therapeutic medicine for treating patients with HIV infection. The impact of lopinavir LED to a boost in the antifungal effects of azole agents on *Aspergillus fumigatus*. This effect demonstrates value in treating azole-resistant *A. fumigatus* infections because it enables resistance strains to become manageable by azoles.

The joint usage of LPV with either itraconazole (ITC) or posaconazole (POS) resulted in powerful synergy against *Aspergillus* test isolates according to research by Burns et al. [68]. The antifungal effect of lopinavir becomes synergistic when paired with itraconazole or posaconazole against different strains of *Aspergillus* in laboratory culture. Lower drug dosages become possible when these two agents combine synergistically since their joint force exceeds the simple additive effects thus minimizing possible toxicity risks.

Additional research determined that azole drugs worked together with LPV because of their ability to block efflux pumps [68]. Proteins known as efflux pumps actively remove drugs from fungal cells which causes their cell concentration to decrease thus reducing their effect on the organism. The antifungal activity of azoles becomes more effective when Lopinavir stops efflux pumps from removing drugs from *Aspergillus fumigatus* cells thus raising azoles' intracellular drug levels. The synergy between lopinavir and azoles is largely enabled by this mechanism of inhibiting efflux pumps. [Table 1](#).

8.5. Immunomodulation

Immunotherapeutic therapeutic strategies work to boost immune system response against *Aspergillus*

Table 1. Summary of antifungal combinations.

Combination Used	Drug Classes Involved	Mechanism or Benefit	Clinical or Experimental Outcomes	Limitations or Toxicity Notes	References
Azoles + Echinocandins	Triazoles, Echinocandins	Synergy, broader spectrum, overcome resistance	Improved outcomes in refractory aspergillosis	Drug–drug interactions with azoles; species-specific differences	[59,63,70]
Caspofungin + Amphotericin B	Echinocandin, Polyene	Synergistic interactions	Potential in treating cerebral <i>phaeohyphomycosis</i>	Increased risk of nephrotoxicity	[64,71]
Caspofungin + Flucytosine	Echinocandin, Antimetabolite	Synergy; broadens spectrum	Improved outcomes in cerebral <i>phaeohyphomycosis</i>	Flucytosine resistance; bone marrow suppression	[64]
Voriconazole + Caspofungin	Triazole, Echinocandin	Improved survival in some <i>Aspergillus</i> infections	Effective in <i>A. fumigatus</i> infections; clinical success in transplant patients	Renal failure, drug interactions	[66,71]
Isavuconazole + Echinocandins	Triazole, Echinocandin	Potential synergy; variable <i>in vitro</i> effects	<i>In vitro</i> indifference or synergy; species-dependent activity	Limited clinical data; species-specific differences	[67]
Posaconazole + Lopinavir	Triazole, Antiviral	Efflux pump inhibition; restores azole susceptibility	Synergistic activity against <i>Aspergillus</i> isolates	Requires further clinical validation	[68]

infections [69]. The immune system of immunocompromised patients lacks the ability to naturally eliminate infections in their body [69]. Scientific teams work on two potential therapeutic techniques involving the usage of immune cells targeting *Aspergillus* antigens which include adoptive immunotherapy with T cells and dendritic cells [69]. Cytokine therapy stands among the current research approaches that use immune response stimulating molecules [69]. Antibody-based remedies demonstrate potential by targeting particular *Aspergillus* substance antigens [69]. Experimental immunotherapeutic treatments may increase treatment success for aspergillosis in high-risk patients despite being still under development.

9. Drug–drug interactions in antifungal combinations

9.1. Cytochrome P450 (CYP) interactions with azoles

The azolic substrates which also function as CYP isoenzyme inhibitors result in various drug–drug interactions [70]. Many drugs require the cytochrome P450 (CYP) enzyme system for their body metabolism since this enzyme family performs drug metabolism. The combination of inhibition and metabolism capabilities by azoles toward CYP enzymes produces multiple drug interactions.

Voriconazole shows both non-linear drug dynamics and sensitivity to CYP polymorphic variations that determine metabolism rates in patients [71]. The primary enzyme responsible for processing Voriconazole through metabolism is CYP2C19

yet its work is affected by genetic variations that create varying enzyme activity throughout the population. Each person experiences different levels of voriconazole due to this variable drug absorption which results in extreme high or low levels throughout the population. The pharmacokinetics of voriconazole demonstrate non-proportional drug level increases as dose amounts rise. The unpredictability of the appropriate dose of voriconazole affects its administration to individual patients.

The drug concentrations undergo major changes during these interactions because they directly affect treatment results [71]. Azoles can create two distinct scenarios during drug–drug interactions by altering levels of other medications which could result in toxicity or treatment failure. Patients need regular drug-level checks and dose readjustments when managing these drug interactions.

9.2. Interactions with echinocandins

Drug–drug interactions are less likely to happen with echinocandins compared to azoles yet certain interactions between medications might still occur [70]. The CYP-based enzyme metabolism system primarily responsible for azole drugs does not affect echinocandins therefore echinocandins exhibit lower drug–drug interaction potential compared to azoles. Certain drugs affecting liver function may result in drug interactions but other interactions remain minimal with echinocandins.

The liver enzyme-mediated metabolism of Caspofungin and micafungin does not involve CYP

enzymes yet they remain vulnerable to other administered drugs [70]. The liver metabolizes caspofungin as well as micafungin yet neither enzyme relies on CYP to complete its metabolic pathway. Drugs influencing enzymes which metabolize caspofungin and micafungin cause changes to their blood levels.

Echinocandins exhibit drug interactions with other medications which medical professionals should monitor during combined medication use [70]. Echinocandins demonstrate good tolerance yet doctors need to monitor patients following any detected echinocandin-related drug interactions.

9.3. Other relevant drug–drug interactions

Amphotericin B has drug interactions with other nephrotoxic medications which raise the possibility of kidney damage [71]. Nephrotoxicity caused by Amphotericin B becomes worse when this medication is given alongside nephrotoxic drugs such as aminoglycosides, cyclosporine and tacrolimus.

Flucytosine depends mostly on kidney elimination so any substance which causes kidney dysfunction will update its blood levels [70]. Organic compounds such as flucytosine readily leave the body through kidneys which means kidney function-altering drugs modify its blood levels causing possible harmful effects and therapeutic outcome reduction.

The successful management of these drug interactions requires constant monitoring as well as appropriate dose adjustments [70]. Medical staff must carefully measure renal function as well as flucytosine levels throughout the treatment period that combines multiple drugs.

10. Drug–food interactions in antifungal therapy

10.1. Impact of food on azole absorption

Food affects significantly the absorption levels of azoles which include itraconazole and posaconazole [71,72]. The gastric pH levels together with food intake in the stomach strongly influence how the body absorbs itraconazole and posaconazole medications. The acidic environment created by food helps drugs such as these absorb better.

Bioavailability of certain medications makes better with food administration [72]. Food administration improves bioavailability for itraconazole and posaconazole oral solution and delayed-release tablets according to their product specifications. Patients taking these drugs may benefit from food since

stomach acidity rises which leads to better drug absorption.

Doctors need to teach their patients the right method of taking these medications in relation to food consumption [71]. Patients require education about itraconazole and posaconazole drug administration procedures with food because this approach enhances drug absorption and leads to better therapeutic results in treatment.

10.2. Dietary restrictions and considerations

The consumption of particular foods may require limitation to decrease drug–food interactions [71]. Doctors may require patients to maintain certain dietary limitations when they use azole antifungal agents to avoid drug–food interactions. Itraconazole and posaconazole patients must avoid taking medications or antacids which reduce stomach acid levels because these substances decrease the absorption of these drugs.

Medical guidance shows patients to abstain from grapefruit juice consumption because it reduces CYP enzyme function and changes azole drug metabolisms [71]. Consuming grapefruit juice leads to liver enzyme inhibition and thus changes the breakdown of azole antifungal drugs in the bloodstream. The increase of drug levels in the blood increased the risk of adverse reactions.

People seeking assistance from pharmacists or dietitians will receive guidance about dietary aspects related to their treatment [71]. When patients seek advice from pharmacists or dietitians they receive guidance about medication proper use alongside dietary safety measures.

10.3. Effects on drug absorption

Absorption rates of posaconazole rise when patients use it with high-fat foods or nutritional supplements based on studies [71,72]. Taking posaconazole with food containing a high amount of fat along with nutritional supplements leads to a marked increase in drug absorption rates. The acidifying effect of fat on stomach contents enhances posaconazole absorption levels in the body.

Medical professionals should monitor drug levels because itraconazole absorption shows inconsistent patterns [71]. Different patient characteristics alongside food intake and gastric pH affect how itraconazole absorbs into the body. Clinical laboratories need to monitor the medication levels to guarantee patients receive enough drug concentration.

Drugs must be administered with proper food consideration because it delivers better results in

fungal treatments [71]. The assessment of drug–food interactions represents a vital step for reaching the best possible outcomes with antifungal therapy when using azole antifungal agents. Healthcare providers need to instruct patients about how to give their medicines correctly in relation to food and dietary limitations for achieving the best possible drug absorption results and treatment success.

11. Toxicity concerns with antifungal combinations

11.1. Increased risk of nephrotoxicity

Medical practitioners should avoid using antifungal combinations containing amphotericin B with nephrotoxic agents since it intensifies the potential damage to kidney cells [71]. The nephrotoxic properties of Amphotericin B become more dangerous when doctors combine this medication with nephrotoxic agents including aminoglycosides, cyclosporine and tacrolimus.

The correct monitoring of renal function becomes essential during antifungal treatment that combines different agents [71]. Healthcare providers must perform regular monitoring of renal function for patients receiving amphotericin B when they take concurrent nephrotoxic medications. Medical staff should assess serum creatinine levels together with blood urea nitrogen (BUN) measurements and monitor urine output.

The use of lipid-formulated amphotericin B represents an alternative approach for reducing this risk according to documentation [73]. The renal toxicity of amphotericin B deoxycholate becomes significantly reduced when medical practitioners use its lipid-formulated version. When giving amphotericin B in combination with other nephrotoxic agent's medical staff should use lipid formulations since these can help reduce the potential nephrotoxic effects.

11.2. Hepatotoxicity and liver enzyme elevations

Antifungal combinations have been demonstrated to raise the possibility of liver injury as well as liver enzyme elevation reports [71]. The hepatotoxic effects of azoles increase when these drugs are combined with other hepatotoxic medications.

Azoles specifically cause liver damage that requires periodic checking of liver function tests [70]. Treatment by azoles in the liver leads to hepatic metabolism that might occasionally trigger liver damage. Medical professionals must track alanine

aminotransferase (ALT) along with aspartate aminotransferase (AST) liver function tests when using azole medications.

People who already have liver conditions face increased danger [71]. Individuals who already have liver diseases face an elevated danger for hepatotoxic complications from azole antifungal drugs and related hepatotoxic antifungal drugs.

11.3. Other potential adverse effects

Medicinal combinations elevate patients' susceptibility to other negative effects from reactions during infusion procedures as well as electrolyte disruptions [71]. Other adverse effects grow in risk when patients receive combination therapy because these treatment protocols can trigger infusion-related reactions and electrolyte imbalances together with drug–drug interaction risks.

Monitoring these associated side effects alongside proper management requires strict attention [71]. Safe patient outcomes and optimal treatment results need active monitoring alongside effect management to protect patient safety.

Medical professionals must evaluate the risks against benefits of combination therapy during clinical decision-making processes [71]. A thorough evaluation process must determine how combination therapy risks compare against its benefits when making clinical decisions. The assessment process for combination therapy by healthcare providers requires a weight-based evaluation of both better treatment outcomes alongside resistance reduction versus elevated toxicity along with drug–drug interactions.

12. Mechanisms of antifungal resistance

The development of antifungal resistance poses a significant danger to proper aspergillosis disease management according to three research articles [47,78,79]. Anti-fungal resistance develops from dual factors such as antifungal drug pressure and fungal pathogens' natural ability to adapt [47,78,79]. Clenching down the resistance mechanisms remains essential to create plans which defeat this problem.

Different mechanisms are responsible for antifungal resistance in *Aspergillus* species. For example, mutations in the ERG11 gene, which encode lanosterol 14-demethylase, confer increased resistance to the drug, azole [47,55]. Similarly, mutations in the FKS genes that are responsible for encoding for 1,3-D-glucan synthase can also lead to echinocandin resistance [47]. Overexpression of certain efflux

pumps also represents an important mechanism of resistance [47,55,79]. Increased expression of efflux pumps leads to the active expulsion of antifungal drugs from the fungal cell. This active transport results in lower drug concentration within the cell making the fungal cell resistant to the antifungal agent [47,79]. Alterations in the cell wall structure such as changes in 1,3-D-glucan and chitin content may also limit the ability of the drug to penetrate the cell and hinder its accessibility to the target site [55]. Last, but not least, the more conservative alterations like metabolic changes that help fungi endure antifungal agents can also bring resistance [55]. All these mechanisms that have been put forward indicate a great diversity of antifungal resistance and hence the necessity of using different approaches to treat it.

13. Overcoming resistance

13.1. Novel agents and combination strategies

Antifungal therapy can become more effective through new drug substances alongside new drug delivery methods and particular treatment protocols [74]. The medical need for antifungal agents with different mechanisms of action stands essential for defeating antifungal resistance in modern medicine. Scientists have discovered new delivery methods for existing antifungal medications which result in superior bioavailability together with decreased toxic properties. The analysis of fresh mixture therapies enables scientists to discover beneficial antifungal combinations which demonstrate better performance than individual treatments do.

Novel antifungal agents with transformed chemical structures need development to fight invasive fungal diseases [75]. Structural changes made to currently used antifungal compounds help doctors fight fungal resistance while enhancing the drugs' performance against resistant fungi. Scientists modify biological compounds by adding and subtracting chemical groups as well as creating novel framework designs in their molecules.

The use of Hsp90 represents an essential therapeutic approach that better treats infections by strengthening existing antifungal treatments and preventing drug resistance while offering general pathway coverage [76]. Hsp90 functions as a molecular chaperone to help stabilize and fold multiple proteins including proteins connected to antifungal resistance. The blocking of Hsp90 activates antifungal resistance mechanisms which lead to strengthening of current antifungal drugs.

13.2. Therapeutic drug monitoring (TDM)

Therapeutic drug monitoring remains disputed for clinical practice because researchers have insufficient information [74]. The procedure of therapeutic drug monitoring requires blood tests which monitor antifungal agent concentrations to maintain optimum drug levels that minimize patient toxicity risk. TDM provides effective benefits to certain antifungal drugs yet remains questionable because of absent data together with expensive and complex testing.

TDM provides a method to optimize antifungal treatments for specific patients [71]. Through therapeutic drug monitoring patients receive the appropriate amount of antifungal medication thus minimizing toxic effects. It is crucial to perform TDM specifically in cases of antifungal agents that possess restricted therapeutic windows and show substantial variations in pharmacokinetic responses.

Through therapeutic drug monitoring patients can receive effective drug levels in their systems without becoming toxic [71]. The blood test analysis under TDM determines which patients need additional drug doses so their medication exposure reaches optimal levels. Through TDM medical staff can identify individual patients vulnerable to drug toxicity so they can either decrease medication amounts or stop treatment completely.

13.3. Alternative treatment options

The treatment recommendation for azole-resistant aspergillosis includes liposomal amphotericin B or a combination of voriconazole with an echinocandin [39]. Patients with azole-resistant aspergillosis benefit from receiving treatment with liposomal amphotericin B or through the combination of voriconazole alongside echinocandin drugs. The antifungal drug liposomal amphotericin B shows superior kidney protection compared to traditional amphotericin B deoxycholate whereas the combination of voriconazole and an echinocandin creates complementary antifungal action.

Studies show combination therapy might represent an option to enhance treatment success [57]. Doctors use combined drug therapy as an effective strategy to enhance the treatment results for patients suffering from invasive fungal infections. Multiple simultaneous targets inside the fungal cell become disruptable through combination therapy which performs better than a single antifungal medication approach.

Healthcare providers use combination therapy as a treatment approach for poor responses to

antifungal treatments of *Candida* infections [77]. Healthcare providers use combination therapy empirically for refractory *Candida* infections which do not react to conventional antifungal treatments for better patient outcomes. Multi-layer antifungal treatment which utilizes agents with different mechanisms of action provides the best possibility of treatment success.

14. Diagnostic advancements in aspergillosis

A timely and correct diagnosis is essential for appropriate aspergillosis management [80]. High-performance computing may also hold promise to improve its standard, although diagnostic paradigms like microscopy and culture remain indispensable as more classical complex yet, not entirely foolproof paradigms [81]. Microscopy has its difficulties because species of *Aspergillus* have similar morphology to other fungi, and culture can take time, delaying therapy [81]. The reality of the disease has been alleviated by advances in molecular diagnostics that have accelerated the diagnosis of aspergillosis and increased its specificity.

Aspergillus DNA can be detected directly from clinical specimens with rapidity and sensitivity—using polymerase chain reaction (PCR)—based assays [81,82]. These assays can identify fungal DNA when they are present at low levels, which increases the sensitivity of diagnosis [81,82]. In addition, PCR can detect specific *Aspergillus* species, which can assist targeted therapy decision making [81,82]. The serological tests that consist in the identification of antibodies to *Aspergillus* antigens are useful in the diagnosis of some specific clinical presentations (such as allergic bronchopulmonary aspergillosis [83]. Nevertheless, serological testing has limitations for the diagnosis of invasive aspergillosis, as the antibody response may be variable and delayed [83]. Imaging techniques may be useful to identify some characteristic lesions that are suggestive of aspergillosis, including high-resolution computed tomography (HRCT) of the lungs

[84]. Although HRCT gives useful informations, it is not conclusive for the diagnosis and should be correlated with clinical findings and laboratory results [84]. The identification of new disease biomarkers that can be detected in serum or other body fluids could improve early diagnosis and monitoring of the disease [85,86]. Some of these methods are still being developed, but they can be much more rapid and accurate than traditional methods, allowing for quicker identification of aspergillosis.

15. Case studies of aspergillosis

Below is a review of five case studies in *Aspergillus* infections to display the various disease presentations and treatment options for different manifestations of this common disease. All cases are described using a case summary table that provides details about the demographic characteristics, clinical presentation, diagnostic workup, treatment plan, complications and outcome. Cases include IPA [87,88], COVID-related PA (CAPA) [89,90], CPA [91,92], ABPA [9,93] and *Aspergillus* Sinusitis [94]. This information is extracted from different studies that looked at this problem of expanding *Aspergillus* infections and Management [87–94]. Keep in mind that some of the data are informally collected from various studies due to the imposed limitations of the scant information available in the provided datasets. These newly described infections remain enigmatic and future studies are needed to clarify what drives these complicated infections. Deteriorating diagnostic capacity, especially in the differential diagnosis between colonization and invasive disease is underlined [12]. Several aspects of efficacy and safety of antifungals are presented [95,96], followed the evolving challenges in dealing with drug resistance as well as drug–disease interactions. After the discussed comorbidities (e.g., COPD and diabetes) are taken into account, and their role on prognosis and management of aspergillosis [97,98].

15.1. Case studies: Table 2

Table 2. Case studies of aspergillosis.

Table 2.1: Case Study 1: Invasive Pulmonary Aspergillosis (IPA)

Variable	Value
Patient Details	
Age	62
Gender	Male
Medical History	Acute Myeloid Leukemia, recent chemotherapy [105]
Post-COVID	No

(continued on next page)

Table 2. (continued)

Table 2.1: Case Study 1: Invasive Pulmonary Aspergillosis (IPA)

Variable	Value
Clinical Presentation	
Symptoms	Fever, cough, dyspnea, chest pain [87]
Duration	10 days [Inferred based on typical IPA onset]
Severity	Severe, requiring hospitalization [87]
Diagnostic Workup	
Galactomannan	Positive [101]
β-D-glucan	Positive [101]
Culture	* <i>Aspergillus fumigatus</i> * isolated from bronchoalveolar lavage [5]
Imaging (CT scan)	Pulmonary infiltrates, cavitations [87]
Treatment Plan	
Antifungal Drugs	Liposomal Amphotericin B [106]
Dosage	3 mg/kg/day [106]
Duration	6 weeks [103]
Response	Partial response [Inferred based on typical response rates to Liposomal Amphotericin B]
Complications & Outcome	
Drug Resistance	No
Relapses	No
Recovery Status	Improved, but with persistent lung damage [Inferred based on typical IPA outcomes]

Table 2.2: Case Study 2: COVID-19-Associated Pulmonary Aspergillosis (CAPA)

Variable	Value
Patient Details	
Age	78
Gender	Female
Medical History	Chronic Obstructive Pulmonary Disease (COPD), diabetes, recent COVID-19 infection requiring intubation [89,98]
Post-COVID	Yes
Clinical Presentation	
Symptoms	Persistent fever, worsening cough, dyspnea, hypoxia despite COVID-19 treatment [89]
Duration	2 weeks post-COVID-19 diagnosis [89]
Severity	Severe, requiring ICU admission [89]
Diagnostic Workup	
Galactomannan (BAL)	Positive [89]
β-D-glucan	Not performed [89]
Culture (BAL)	* <i>Aspergillus fumigatus</i> * isolated [89]
Imaging (CT scan)	New pulmonary infiltrates, worsening of pre-existing COPD findings [89]
Treatment Plan	
Antifungal Drugs	Voriconazole [89]
Dosage	Not specified [89]
Duration	Ongoing at the time of reporting [89]
Response	No clear response reported at the time of reporting [89]
Complications & Outcome	
Drug Resistance	Not assessed
Relapses	Not reported
Recovery Status	Patient still in ICU at the time of reporting; high mortality risk [89]

Table 2.3: Case Study 3: Chronic Pulmonary Aspergillosis (CPA)

Variable	Value
Patient Details	
Age	55
Gender	Male
Medical History	Tuberculosis (TB), history of cavitory lung lesions [91,92]
Post-COVID	No
Clinical Presentation	
Symptoms	Chronic cough, hemoptysis, fatigue, weight loss [91]
Duration	Several months [91]
Severity	Moderate to severe, impacting quality of life [91]

(continued on next page)

Table 2. (continued)

Table 2.3: Case Study 3: Chronic Pulmonary Aspergillosis (CPA)

Variable	Value
Diagnostic Workup	
Galactomannan	Negative [91]
β-D-glucan	Not performed [91]
Culture	Negative [91]
Imaging (CT scan)	Multiple cavities in the upper lobes, no fungal balls [91]
Serology (<i>Aspergillus</i> precipitins)	Positive [91]
Treatment Plan	
Antifungal Drugs	Itraconazole [91]
Dosage	Not specified [91]
Duration	Several months [91]
Response	Improved or stabilized in 71 % of patients [91]
Complications & Outcome	
Drug Resistance	Not reported
Relapses	Common [91]
Recovery Status	Variable, with some patients achieving long-term improvement, others experiencing relapses [91]

Table 2.4: Case Study 4: Allergic Bronchopulmonary Aspergillosis (ABPA)

Variable	Value
Patient Details	
Age	30
Gender	Female
Medical History	Asthma, cystic fibrosis [93,107]
Post-COVID	No
Clinical Presentation	
Symptoms	Recurrent wheezing, cough, sputum production, fever, eosinophilia [9]
Duration	Several months [9]
Severity	Variable, ranging from mild to severe exacerbations [9]
Diagnostic Workup	
Galactomannan	May be positive or negative [9]
β-D-glucan	Not routinely performed [9]
Culture	Often negative [9]
Imaging (HRCT)	Central bronchiectasis, high-attenuation mucus plugging [107]
Serology	Elevated <i>Aspergillus</i> -specific IgE and IgG antibodies, eosinophilia [9]
Treatment Plan	
Antifungal Drugs	Itraconazole [94]
Dosage	Not specified [94]
Duration	Long-term [94]
Response	Improvement in symptoms and lung function [93]
Additional Treatment	Corticosteroids for symptom control [94]
Complications & Outcome	
Drug Resistance	Not a primary concern in ABPA [94]
Relapses	Possible [9]
Recovery Status	Variable, with some patients achieving long-term control, others experiencing recurrent exacerbations [93]

Table 2.5: Case Study 5: *Aspergillus* Sinusitis

Variable	Value
Patient Details	
Age	45
Gender	Male
Medical History	Diabetes, immunocompromised due to poorly controlled diabetes [98]
Post-COVID	No
Clinical Presentation	
Symptoms	Facial pain, nasal congestion, purulent nasal discharge, headache [94]
Duration	Several weeks [94]
Severity	Moderate, with potential for complications if untreated [94]
Diagnostic Workup	
Galactomannan	May be positive [94]
β-D-glucan	Not routinely used for sinusitis [94]

(continued on next page)

Table 2. (continued)

Table 2.5: Case Study 5: *Aspergillus* Sinusitis

Variable	Value
Culture	<i>*Aspergillus fumigatus*</i> isolated from nasal secretions [94]
Imaging (CT scan)	Sinus opacification, mucosal thickening [94]
Treatment Plan	
Antifungal Drugs	Itraconazole [94]
Dosage	Not specified [94]
Duration	Several weeks to months [94]
Response	Resolution of symptoms [94]
Complications & Outcome	
Drug Resistance	Unlikely in uncomplicated sinusitis [94]
Relapses	Possible, especially with poorly controlled diabetes [98]
Recovery Status	Complete resolution of sinusitis with appropriate treatment [94]

16. Discussion

This set of case studies stresses the need of a comprehensive diagnosis workup and personalized therapy plans by showing the many medical presentations of *Aspergillus* infections. Particularly in non-neutropenic patients and those with severe asthma coordinated diagnostic standards and better diagnostic tools are urgently needed given the diagnostic difficulties [66]. The different reactions to antifungal treatment underline the complexity of these diseases and the urgency of continual research into new therapeutic solutions, including the possible role of combination therapy and host-directed therapies [13,99]. Particularly in immunocompromised patients, the high mortality connected with several kinds of aspergillosis drives home the need of early diagnosis and quick therapy. Particularly in the setting of emerging contagious diseases like COVID-19 [98,100], more study is needed to enhance our knowledge of the pathobiology, diagnosis, and treatment of these infections. Pre-existing lung disease and immunosuppression clearly play a role in raising *Aspergillus* infection susceptibility throughout the case studies [87,97,98]. Furthermore, mentioned are the shortcomings of present diagnostic tools, including the varying sensitivity and specificity of galactomannan and β -D-glucan tests [101,102]. Among the numerous considerations that influence the choice of antifungal treatment are the precise *Aspergillus* species, the extent of the infection, and the general health condition of the patient [103,104]. Apart from abuse potential, one should also take into account the possibilities for drug interactions and side effects [96].

Arranged *Aspergillus* case studies offer a great tool for grasping the clinical range of this opportunistic fungi. Though restricted by the information available in the provided papers, the results clearly show that more study is required to maximize diagnosis and treatment methods for different *Aspergillus*

infections. Improved knowledge of host-pathogenesis interactions, together with the growth of new diagnostic tools and antifungal medicines, is essential for enhancing patient results [99,104]. Encouraging studies and guaranteeing efficient management of this varied group of diseases depend on standardized diagnostic criteria and treatment guidelines [12,66]. Especially in high-risk groups [88,97], early detection and quick starting of suitable antifungal treatment are of utmost importance. The challenges of controlling these infections, especially in the setting of co-morbidities and rising infectious diseases, underline the requirement for a multidisciplinary strategy including clinicians, microbiologists, and investigators [98,100].

17. Conclusion: future directions in aspergillosis management

Aspergillosis continues to be a major global health threat, especially among immunosuppressed individuals. Although antifungal therapy is essential in the management of the disease, available agents have limitations, and the emergence of drug resistance makes the discovery of newer therapeutic interventions imperative. The recent development of novel antifungal agents with more favorable efficacy and safety profiles, including rezafungin and ibrexafungerp, is promising. Targeted drug delivery system like Dectin-1 Dextrin-2 targeted liposomes promise a significant increase in the antifungal efficacy and a better profile in terms of toxicity. Other promising routes for enhanced patient outcomes include combination therapy and immunomodulatory strategies.

New, state-of-the-art molecular tests and assays and biomarkers will enable earlier and accurate diagnosis that is currently under active development. It will facilitate timely interventions and therefore increase chances of success with therapy.

A Broad Perspective — Future Directions Research: R&D should move towards a synergistic mix of novel antifungal drugs, diagnostics and immunotherapies. For designing appropriate strategies, we need an integrated knowledge of systems associated with antifungal resistance mechanisms. Effective strategies for the management of aspergillosis will require centralized collaborative care involving clinicians, researchers and public health officials to reduce the burden of this devastating disease on worldwide health. In addition, the incorporation of model-informed drug development (MIDD) will advance the development and delivery of these effective treatments. Further research and development is a necessity to ensure appropriate effective treatments to all those who are afflicted by this deadly disease.

References

- [1] Hagiwara D, Watanabe A, Kamei K, Goldman GH. Epidemiological and genomic landscape of azole resistance mechanisms in *Aspergillus* fungi. *Front Microbiol* 2016;7:1382. Available from: www.frontiersin.org.
- [2] Elad D, Segal E. Diagnostic aspects of veterinary and human aspergillosis. *Front Microbiol* 2018;9:1303. Available from: www.frontiersin.org.
- [3] Desoubreux G, Cray C. Animal models of aspergillosis. *Comp Med* 2018;68:109–23. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29663936>.
- [4] Cunha C, Aversa F, Romani L, Carvalho A. Human genetic susceptibility to invasive aspergillosis. In: Heitman J, editor. *PLoS Pathog*. 2013;9:e1003434. Available from: <https://dx.plos.org/10.1371/journal.ppat.1003434>.
- [5] Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of Aspergillosis: clinical practice guidelines of the infectious diseases Society of America. *Clin Infect Dis* 2008;46:327–60. Available from: <https://academic.oup.com/cid/article/46/3/327/386777>.
- [6] Krishnan S, Manavathu EK, Chandrasekar PH. *Aspergillus flavus*: an emerging non-fumigatus *Aspergillus* species of significance. *Mycoses* 2009;52:206–22. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/j.1439-0507.2008.01642.x>.
- [7] Rudramurthy SM, Paul RA, Chakrabarti A, Mouton JW, Meis JF. Invasive aspergillosis by *Aspergillus flavus*: epidemiology, diagnosis, antifungal resistance, and management. *J Fungi* 2019;5:55. Available from: <https://www.mdpi.com/2309-608X/5/3/55>.
- [8] Chowdhary A, Sharma C, Meis JF. Azole-resistant aspergillosis: epidemiology, molecular mechanisms, and treatment. *J Infect Dis* 2017;216:S436–44. Available from: http://academic.oup.com/jid/article/216/suppl_3/S436/4107054/AzoleResistant-Aspergillosis-Epidemiology.
- [9] Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. *Thorax* 2015;70:270–7. Available from: <https://thorax.bmj.com/content/70/3/270>.
- [10] Nucci M, Queiroz-Telles F, Tobón AM, Restrepo A, Colombo AL. Epidemiology of opportunistic fungal infections in Latin America. *Clin Infect Dis* 2010;51:561–70. Available from: <https://doi.org/10.1086/655683>.
- [11] Marr KA, Platt A, Tornheim JA, Zhang SX, Datta K, Cardozo C, et al. Aspergillosis complicating severe coronavirus disease - volume 27, number 1—January 2021 - emerging infectious diseases journal - CDC. *Emerg Infect Dis* 2021;27:18–25. Available from: https://wwwnc.cdc.gov/eid/article/27/1/20-2896_article.
- [12] Apostolopoulou A, Garrigos ZE, Vijayvargiya P, Lerner AH, Farmakiotis D. Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: a systematic review of the literature. *Diagnostics* 2020;10:807. 2020. Available from: <https://www.mdpi.com/2075-4418/10/10/807/htm>.
- [13] Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P, Krause R, et al. COVID-19 associated pulmonary aspergillosis (CAPA)—from immunology to treatment. *J Fungi* 2020;6:91. 2020 Available from: <https://www.mdpi.com/2309-608X/6/2/91/htm>.
- [14] Dimopoulos G, Almyroudi MP, Myrianthefs P, Rello J. COVID-19-Associated pulmonary aspergillosis (CAPA). *J Intensive Med* 2021;1:71–80.
- [15] Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. *Eur Respir Rev* 2011;20:156–74. Available from: <https://publications.ersnet.org/content/errev/20/121/156>.
- [16] Baddley JW. Clinical risk factors for invasive aspergillosis. *Med Mycol* 2011;49:S7–12. Available from: <https://doi.org/10.3109/13693786.2010.505204>.
- [17] Beernaert LA, Pasmans F, van Waeyenberghe L, Haesebrouck F, Martel A. *Aspergillus* infections in birds: a review. *Avian Pathol* 2010;39:325–31. Available from: <https://www.tandfonline.com/doi/abs/10.1080/03079457.2010.506210>.
- [18] Patel AR, Patel AR, Singh S, Singh S, Khawaja I, Patel AR, et al. Diagnosing allergic bronchopulmonary aspergillosis: a review. *Cureus* 2019;11. Available from: <https://www.cureus.com/articles/19187-diagnosing-allergic-bronchopulmonary-aspergillosis-a-review>.
- [19] Bongomin F, Asio LG, Baluku JB, Kwizera R, Denning DW. Chronic pulmonary aspergillosis: notes for a clinician in a resource-limited setting where there is No mycologist. *J Fungi* 2020;6:75. Available from: <https://www.mdpi.com/2309-608X/6/2/75/htm>.
- [20] Vanderbeke L, Spriet I, Breynaert C, Rijnders BJA, Verweij PE, Wauters J. Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. *Curr Opin Infect Dis* 2018;31:471–80. Available from: https://journals.lww.com/co-infectiousdiseases/fulltext/2018/12000/invasive_pulmonary_aspergillosis_complicating.3.aspx.
- [21] Latgé JP, Beauvais A, Chamilos G. The cell wall of the human fungal pathogen *Aspergillus fumigatus*: biosynthesis, organization, immune response, and virulence. *Annu Rev Microbiol* 2017;71:99–116. Available from: <https://www.annualreviews.org/content/journals/10.1146/annurev-micro-030117-020406>.
- [22] Shibuya K, Paris S, Ando T, Nakayama H, Hatori T, Latgé JP. Catalases of *Aspergillus fumigatus* and inflammation in aspergillosis. *Nippon Ishinkin Gakkai Zasshi* 2006;47:249–55.
- [23] Tochigi N, Okubo Y, Ando T, Wakayama M, Shinozaki M, Gocho K, et al. Histopathological implications of *Aspergillus* infection in lung. *Mediators Inflamm* 2013;2013:809798. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1155/2013/809798>.
- [24] Sales-Campos H, Tonani L, Cardoso CRB, Kress MRVZ. The immune interplay between the host and the pathogen in *Aspergillus fumigatus* lung infection. *BioMed Res Int* 2013;2013:693023. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1155/2013/693023>.
- [25] Knutsen AP. Allergic bronchopulmonary aspergillosis in asthma. *Expert Rev Clin Immunol* 2017;13:11–4. Available from: <https://www.tandfonline.com/doi/abs/10.1080/1744666X.2017.1232620>.
- [26] Gamaletsou MN, Rammaert B, Bueno MA, Sipsas NV, Moriyama B, Kontoyiannis DP, et al. *Aspergillus* arthritis: analysis of clinical manifestations, diagnosis, and treatment of 31 reported cases. *Med Mycol* 2017;55:246–54. Available from: <https://doi.org/10.1093/mmy/myw077>.

- [27] Shankar S, Mahadevan A, Sundaram C, Sarkar C, Chacko G, Lanjewar D, et al. Pathobiology of fungal infections of the central nervous system with special reference to the Indian scenario. *Neuro India* 2007;55:198–215. Available from: <https://pubmed.ncbi.nlm.nih.gov/17921648/>.
- [28] de Boer MGJ, Jolink H, Halkes CJM, van der Heiden PLJ, Kremer D, Falkenburg JHF, et al. Influence of polymorphisms in innate immunity genes on susceptibility to invasive aspergillosis after stem cell transplantation. *PLoS One* 2011;6:e18403. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0018403>.
- [29] Rapaka RR, Kolls JK. Pathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis: current understanding and future directions. *Med Mycol* 2009;47: S331–7. Available from: <https://doi.org/10.1080/13693780802266777>.
- [30] Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. *Eur Respir J* 2015;47:45–68. Available from: <https://publications.ersnet.org/content/erj/47/1/45>.
- [31] Patel AR, Patel AR, Singh S, Singh S, Khawaja I, Patel AR, et al. Treating allergic bronchopulmonary aspergillosis: a review. *Cureus* 2019;11:e4538. Available from: <https://www.cureus.com/articles/19316-treating-allergic-bronchopulmonary-aspergillosis-a-review>.
- [32] Jat K, Vaidya P, Mathew J, Jondhale S, Singh M. Childhood allergic bronchopulmonary aspergillosis. *Lung India* 2018;35: 499–507. Available from: https://journals.lww.com/lungindia/fulltext/2018/35060/childhood_allergic_bronchopulmonary_aspergillosis.9.aspx.
- [33] Krishnan S, Manavathu EK, Chandrasekar PH. *Aspergillus flavus*: an emerging non-fumigatus *Aspergillus* species of significance. *Mycoses* 2009;52:206–22. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1439-0507.2008.01642.x>.
- [34] Peral-Cagigal B, Redondo-González L-M, Verrier-Hernández A. Invasive aspergillosis journal section: oral surgery. *J Clin Exp Dent* 2014;6:448–51. Available from: <https://doi.org/10.4317/jced.51571>.
- [35] Reischies F, Hoenigl M. The role of surgical debridement in different clinical manifestations of invasive aspergillosis. *Mycoses* 2014;57:1–14. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/myc.12224>.
- [36] Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azole-resistant *Aspergillus fumigatus* strains due to agricultural azole use creates an increasing threat to human health. *PLoS Pathog* 2013;9:e1003633. Available from: <https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003633>.
- [37] Chowdhary A, Sharma C, Hagen F, Meis JF. Exploring azole antifungal drug resistance in *Aspergillus fumigatus* with special reference to resistance mechanisms. *Future Microbiol* 2014;9:697–711. Available from: <https://www.tandfonline.com/doi/abs/10.2217/fmb.2014.27>.
- [38] Bader O, Weig M, Reichard U, Lugert R, Kuhns M, Christner M, et al. Cyp51A-based mechanisms of aspergillus fumigatus azole drug resistance present in clinical samples from Germany. *Antimicrob Agents Chemother* 2013;57:3513–7. Available from: <https://journals.asm.org/doi/10.1128/aac.00167-13>.
- [39] Meis JF, Chowdhary A, Rhodes JL, Fisher MC, Verweij PE. Clinical implications of globally emerging azole resistance in *Aspergillus fumigatus*. *Philos Trans R Soc B Biol Sci* 2016;371:20150460. Available from: <https://royalsocietypublishing.org/doi/10.1098/rstb.2015.0460>.
- [40] Hagiwara D, Miura D, Shimizu K, Paul S, Ohba A, Gonoi T, et al. A novel Zn2-Cys6 transcription factor AtrR plays a key role in an azole resistance mechanism of *Aspergillus fumigatus* by Co-regulating cyp51A and cdr1B expressions. *PLoS Pathog* 2017;13:e1006096. Available from: <https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006096>.
- [41] Hare Jensen R, Marie K, Astvad T, Silva LV, Sanglard D, Jørgensen R, et al. Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in *Candida albicans* orchestrated by multiple genetic alterations. *J Antimicrob Chemother* 2015;70:2551–5. Available from: <https://academic.oup.com/jac/article/70/9/2551/720669>.
- [42] Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. *Lancet Infect Dis* 2017;17: e383–92. Available from: <https://pubmed.ncbi.nlm.nih.gov/28774698/>.
- [43] Carmo A, Rocha M, Pereirinha P, Tomé R, Costa E. Antifungals: from pharmacokinetics to clinical practice. *Antibiotics* 2023;12:884. Available from: <https://www.mdpi.com/2079-6382/12/5/884/htm>.
- [44] Houšť J, Spížek J, Havlíček V. Antifungal drugs. *Meta* 2020; 10:106. Available from: <https://www.mdpi.com/2218-1989/10/3/106/htm>.
- [45] Ambati S, Ferraro AR, Kang SE, Lin J, Lin X, Momany M, et al. Dectin-1-Targeted antifungal liposomes exhibit enhanced efficacy. *mSphere* 2019;4:e00025–19. Available from: <https://journals.asm.org/doi/10.1128/mSphere.00025-19>.
- [46] Posch W, Blatzer M, Wilflingseder D, Lass-Flörl C. *Aspergillus terreus*: novel lessons learned on amphotericin B resistance. *Med Mycol* 2018;56:S73–82. Available from: <https://doi.org/10.1093/mmy/myx119>.
- [47] Gamaletsou MN, Walsh TJ, Sipsas NV. Invasive fungal infections in patients with hematological malignancies: emergence of resistant pathogens and new antifungal therapies. *Turkish J Hematol*. 2018;35:1–11.
- [48] Beer KD, Farnon EC, Jain S, Jamerson C, Lineberger S, Miller J, et al. Multidrug-resistant *Aspergillus fumigatus* carrying mutations linked to environmental fungicide exposure — three states, 2010–2017. *MMWR Morb Mortal Wkly Rep* 2019;67:1064–7. Available from: <https://www.cdc.gov/mmwr/volumes/67/wr/mm6738a5.htm>.
- [49] Beardsley J, Halliday CL, Chen SC-A, Sorrell TC, Halliday C, Chen S, et al. Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside. *Future Microbiol* 2018;13:1175–91. Available from: <https://www.tandfonline.com/doi/abs/10.2217/fmb-2018-0059>.
- [50] Fisher BT, Zaoutis T, Dvorak CC, Nieder M, Zerr D, Wingard JR, et al. Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial. *JAMA* 2019;322:1673–81. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2753898>.
- [51] Rauseo AM, Coler-Reilly A, Larson L, Spec A. Hope on the horizon: novel fungal treatments in development. *Open Forum Infect Dis* 2020;7:ofaa016. Available from: <https://doi.org/10.1093/ofid/ofaa016>.
- [52] Miesel L, Cushion MT, Ashbaugh A, Lopez SR, Ong V. Efficacy of rezafungin in prophylactic mouse models of invasive candidiasis, aspergillosis, and pneumocystis pneumonia. *Antimicrob Agents Chemother* 2021;65:e01992–20. Available from: <https://journals.asm.org/doi/10.1128/aac.01992-20>.
- [53] Miesel L, Lin KY, Ong V. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: insights on the PK/PD pharmacometrics of rezafungin efficacy. *Pharmacol Res Perspect* 2019;7:e00546. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/prp2.546>.
- [54] Angulo DA, Alexander B, Rautemaa-Richardson R, Alastruey-Izquierdo A, Hoenigl M, Ibrahim AS, et al. Ibexafungerp, a novel triterpenoid antifungal in development for the treatment of mold infections. *J Fungi* 2022;8:1121. 2022. Available from: <https://www.mdpi.com/2309-608X/8/11/1121/htm>.
- [55] Lima SL, Colombo AL, de Almeida Junior JN. Fungal cell wall: emerging antifungals and drug resistance. *Front*

- Microbiol 2019;10:492317. Available from: www.frontiersin.org.
- [56] Ambati S, Ellis EC, Lin J, Lin X, Lewis ZA, Meagher RB. Dectin-2-Targeted antifungal liposomes exhibit enhanced efficacy. *mSphere* 2019;4:e00715-19. Available from: <https://journals.asm.org/doi/10.1128/msphere.00715-19>.
 - [57] Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. Combination treatment of invasive fungal infections. *Clin Microbiol Rev* 2005;18:163–94. Available from: <https://doi.org/10.1128/cmr.18.1.163-194.2005?download=true>.
 - [58] Svetaz LA, Postigo A, Butassi E, Zacchino SA, Sortino MA. Antifungal drugs combinations: a patent review 2000-2015. *Expert Opin Ther Pat* 2016;26:439–53. Available from: <https://pubmed.ncbi.nlm.nih.gov/26813798/>.
 - [59] Elefanti A, Mouton JW, Verweij PE, Tsakris A, Zerva L, Meletiadi J. Amphotericin B- and voriconazole-echinocandin combinations against *Aspergillus* spp.: effect of serum on inhibitory and fungicidal interactions. *Antimicrob Agents Chemother* 2013;57:4656–63. Available from: <https://doi.org/10.1128/aac.00597-13?download=true>.
 - [60] Siopi M, Siafakas N, Vourli S, Mouton JW, Zerva L, Meletiadi J. Dose optimization of voriconazole/anidulafungin combination against *Aspergillus fumigatus* using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis. *J Antimicrob Chemother* 2016;71:3135–47. Available from: <https://doi.org/10.1093/jac/dkw276>.
 - [61] Aruanno M, Glampedakis E, Lamothe F. Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside. *Antimicrob Agents Chemother* 2019;63:e00399-19. Available from: <https://doi.org/10.1128/aac.00399-19?download=true>.
 - [62] Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. *Antimicrob Agents Chemother*. Available from: <https://doi.org/10.1128/aac.46.8.2564-2568.2002?download=true>.
 - [63] Jemel S, Raveloarisona Y, Bidaud AL, Djenontin E, Kallel A, Guillot J, et al. In vitro and in vivo evaluation of antifungal combinations against azole-resistant *Aspergillus fumigatus* isolates. *Front Cell Infect Microbiol* 2023;12:1038342.
 - [64] Samaddar A, Mendonsa JM, Sudhaharan S, S N, Kindo AJ, Shetty A, et al. In vitro evaluation of antifungal combinations against neurotropic dematiaceous fungi associated with primary cerebral phaeohyphomycosis. *Microbiol Spectr* 2024;12:e00781-24. Available from: <https://doi.org/10.1128/spectrum.00781-24?download=true>.
 - [65] Khalifa HO, Majima H, Watanabe A, Kamei K. In vitro characterization of twenty-one antifungal combinations against echinocandin-resistant and -susceptible *Candida glabrata*. *J Fungi* 2021;7:108. Available from: <https://www.mdpi.com/2309-608X/7/2/108/htm>.
 - [66] Singh N, Limaye AP, Forrest G, Safdar N, Muñoz P, Pursell K, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. *Transplantation* 2006;81:320–6. Available from: https://journals.lww.com/transplantjournal/fulltext/2006/02150/combination_of_voriconazole_and_caspofungin_as.5.aspx.
 - [67] Raffetin A, Courbin V, Jullien V, Dannaoui E. In vitro combination of isavuconazole with echinocandins against azole-susceptible and -resistant *Aspergillus* spp. *Antimicrob Agents Chemother* 2018;62. Available from: <https://doi.org/10.1128/aac.01382-17?download=true>.
 - [68] Burns N, Salama EA, Seleem MN. Synergistic potential of lopinavir and azole combination therapy against clinically important *Aspergillus* species. *PLoS One* 2024;19:e0314474. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0314474>.
 - [69] Lauruschkat CD, Einsele H, Loeffler J. Immunomodulation as a therapy for *Aspergillus* infection: current status and future perspectives. *J Fungi* 2018;4:137. Available from: <https://www.mdpi.com/2309-608X/4/4/137/htm>.
 - [70] Bellmann R, Smuszkiwicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. *Infection* 2017;45:737–79. Available from: <https://pubmed.ncbi.nlm.nih.gov/28702763/>.
 - [71] Hope WW, Denning DW. Optimising antifungal therapy for individual patients. *Intern Med J* 2004;34:147–9. Available from: <https://doi.org/10.1111/j.1444-0903.2004.00569.x>.
 - [72] Eschenauer GA. Antifungal therapies for *Aspergillus* spp: present and future. *Semin Respir Crit Care Med* 2024;45:61–8. Available from: <http://www.thieme-connect.de/products/ejournals/html/10.1055/s-0043-1776776>.
 - [73] Patterson TF. Treatment of invasive aspergillosis: polyenes, echinocandins, or azoles? *Med Mycol* 2006;44:S357–62. Available from: <https://doi.org/10.1080/13693780600826715>.
 - [74] Chang YL, Yu SJ, Heitman J, Wellington M, Chen YL. New facets of antifungal therapy. *Virulence* 2017;8:222–36. Available from: <https://pubmed.ncbi.nlm.nih.gov/27820668/>.
 - [75] Punia A, Choudhary P, Sharma N, Dahiya S, Gulia P, Chhillar AK. Therapeutic approaches for combating *Aspergillus* associated infection. *Curr Drug Targets* 2022;23:1465–88. Available from: <https://www.eurekaselect.com/article/124765>.
 - [76] Cowen LE, Singh SD, Köhler JR, Collins C, Zaas AK, Schell WA, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. *Proc Natl Acad Sci USA* 2009;106:2818–23. Available from: <https://doi.org/10.1073/pnas.0813394106?download=true>.
 - [77] Su S, Yan H, Min L, Wang H, Chen X, Shi J, et al. The antifungal activity of caspofungin in combination with antifungals or non-antifungals against *Candida* species in vitro and in clinical therapy. *Expert Rev Anti Infect Ther* 2022;20:161–78. Available from: <https://www.tandfonline.com/doi/abs/10.1080/14787210.2021.1941868>.
 - [78] Arastehfar A, Gabaldón T, Garcia-Rubio R, Jenks JD, Hoenigl M, Salzer HJF, et al. Drug-resistant fungi: an emerging challenge threatening our limited antifungal armamentarium. *Antibiotiques* 2020;9:877. Available from: <https://www.mdpi.com/2079-6382/9/12/877/htm>.
 - [79] Arastehfar A, Lass-Flörl C, Garcia-Rubio R, Daneshnia F, Ilkit M, Boekhout T, et al. The quiet and underappreciated rise of drug-resistant invasive fungal pathogens. *J Fungi* 2020;6:138. Available from: <https://www.mdpi.com/2309-608X/6/3/138/htm>.
 - [80] Zakaria A, Osman M, Dabboussi F, Rafei R, Mallat H, Papon N, et al. Recent trends in the epidemiology, diagnosis, treatment, and mechanisms of resistance in clinical *Aspergillus* species: a general review with a special focus on the Middle Eastern and North African region. *J Infect Public Health* 2020;13:1–10.
 - [81] Fang W, Wu J, Cheng M, Zhu X, Du M, Chen C, et al. Diagnosis of invasive fungal infections: challenges and recent developments. *J Biomed Sci* 2023;301:1–35. Available from: <https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-023-00926-2>.
 - [82] Kidd SE, Chen SCA, Meyer W, Halliday CL. A new age in molecular diagnostics for invasive fungal disease: are we ready? *Front Microbiol* 2020;10:491318. Available from: www.frontiersin.org.
 - [83] Richardson M, Page I. Role of serological tests in the diagnosis of mold infections. *Curr Fungal Infect Rep* 2018;12:127–36. Available from: <https://link.springer.com/article/10.1007/s12281-018-0321-1>.
 - [84] Verweij PE, Brüggemann RJM, Azoulay E, Bassetti M, Blot S, Buil JB, et al. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. *Intensive Care Med* 2021;47:819–34. Available from: <https://link.springer.com/article/10.1007/s00134-021-06449-4>.

- [85] Ball B, Bermas A, Carruthers-Lay D, Geddes-McAlister J. Mass spectrometry-based proteomics of fungal pathogenesis, host–fungal interactions, and antifungal development. *J Fungi* 2019;5:52. Available from: <https://www.mdpi.com/2309-608X/5/2/52/htm>.
- [86] Rayner CR, Smith PF, Andes D, Andrews K, Derendorf H, Friberg LE, et al. Model-informed drug development for anti-infectives: state of the art and future. *Clin Pharmacol Ther* 2021;109:867–91. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/cpt.2198>.
- [87] Lamoth F, Calandra T, Torres A, Niederman MS. Pulmonary aspergillosis: diagnosis and treatment. *Eur Respir Rev* 2022;31:220114. Available from: <https://publications.ersnet.org/content/errev/31/166/220114>.
- [88] Denning DW. Therapeutic outcome in invasive aspergillosis. *Clin Infect Dis* 1996;23:608–15. Available from: <https://doi.org/10.1093/clinids/23.3.608>.
- [89] Bartoletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Bussini L, et al. Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: a prospective study. *Clin Infect Dis* 2021;73:e3606–14. Available from: <https://doi.org/10.1093/cid/ciaa1065>.
- [90] Verweij PE, Rijnders BJA, Brüggemann RJM, Azoulay E, Bassetti M, Blot S, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. *Intensive Care Med* 2020;46:1524–35. Available from: <https://link.springer.com/article/10.1007/s00134-020-06091-6>.
- [91] Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. *Clin Infect Dis* 2003;37:S265–80. Available from: <https://doi.org/10.1086/376526>.
- [92] Denning DW, Cadranell J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. *Eur Respir J* 2016;47:45–68. Available from: <https://pubmed.ncbi.nlm.nih.gov/26699723/>.
- [93] Lehmann S, Pfannenstiel C, Friedrichs F, Kröger K, Wagner N, Tenbrock K. Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. *Ther Adv Respir Dis* 2014;8:141–9. Available from: <https://journals.sagepub.com/doi/10.1177/1753465814547517>.
- [94] Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by *Aspergillus*. *Clin Infect Dis* 2000;30:696–709. Available from: <https://doi.org/10.1086/313756>.
- [95] Comely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). *Clin Infect Dis* 2007;44:1289–97. Available from: <https://doi.org/10.1086/514341>.
- [96] Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. *Clin Infect Dis* 2008;46:201–11. Available from: <https://doi.org/10.1086/524669>.
- [97] Samarakoon P, Soubani AO. Invasive pulmonary aspergillosis in patients with COPD: a report of five cases and systematic review of the literature 2008;5:19–27. <https://doi.org/10.1177/1479972307085637>; <https://journals.sagepub.com/doi/10.1177/1479972307085637>.
- [98] Casalini G, Giacomelli A, Ridolfo A, Gervasoni C, Antinori S. Invasive fungal infections complicating covid-19: a narrative review. *J Fungi* 2021;7:921. Available from: <https://www.mdpi.com/2309-608X/7/11/921/htm>.
- [99] Heard KL, Hughes S, Mughal N, Moore LSP. COVID-19 and fungal superinfection. *Lancet Microbe* 2020;1:e107. Available from: <http://www.thelancet.com/article/S2666524720300653/fulltext>.
- [100] Rogers TR, Morton CO, Springer J, Conneally E, Heinz W, Kenny C, et al. Combined real-time PCR and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies. *Br J Haematol* 2013;161:517–24. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.12285>.
- [101] Falces-Romero I, Ruiz-Bastán M, Díaz-Pollán B, Maseda E, García-Rodríguez J, Montero-Vega MD, et al. Isolation of *Aspergillus* spp. in respiratory samples of patients with COVID-19 in a Spanish tertiary care hospital. *Mycoses* 2020;63:1144–8. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/myc.13155>.
- [102] Sehgal IS, Dhooria S, Muthu V, Prasad KT, Agarwal R. An overview of the available treatments for chronic cavitary pulmonary aspergillosis. *Expet Rev Respir Med* 2020;14:715–27. Available from: <https://www.tandfonline.com/doi/abs/10.1080/17476348.2020.1750956>.
- [103] Agarwal R, Khan A, Garg M, Aggarwal A, Gupta D. Pictorial essay: allergic bronchopulmonary aspergillosis. *Indian J Radiol Imag* 2011;21:242–52. Available from: <http://www.thieme-connect.de/DOI/DOI?10.4103/0971-3026.90680>.
- [104] Cadranell J, Philippe B, Hennequin C, Bergeron A, Bergot E, Bourdin A, et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. *Eur J Clin Microbiol Infect Dis* 2012;31:3231–9. Available from: <https://link.springer.com/article/10.1007/s10096-012-1690-y>.
- [105] Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. *Haematologica* 2010;95:644–50. Available from: <https://haematologica.org/article/view/5562>.
- [106] Comely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). *Clin Infect Dis* 2007;44:1289–97. Available from: <https://doi.org/10.1086/514341>.
- [107] Permpalung N, Maertens J, Marr KA. Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis. *Lancet Infect Dis* 2021;21:766–7. Available from: <http://www.thelancet.com/article/S1473309921000608/fulltext>.